Alvotech Sees Opportunities Open Up With US Approvals
Executives Discuss Humira And Stelara Rivals, Interchangeability, Partnerships And Pipeline
With long-awaited US approvals now rolling in and a growing pipeline of future biosimilars, further opportunities are opening up for Alvotech – including potentially launching a second interchangeable Stelara biosimilar in the US just a few months after market formation – chief commercial officer Anil Okay and chief strategy officer Ming Li tell Generics Bulletin.
